Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
Aerobic and anaerobic gram +ve and gram -ve bacteria. Clinical selection for Meropenem should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
By intravenous injection over 5 minutes or by intravenous infusion, 500 mg every 8 hours, dose doubled in hospital-acquired pneumonia, peritonitis, septicaemia and infections in neutro- penic patients; child 3 months12 years [not licensed for infection in neutropenia] 10 20 mg/kg every 8 hours, over 50 kg body weight adult dose Meningitis, 2 g every 8 hours; child 3 months12 years 40 mg/kg every 8 hours, over 50 kg body weight adult dose Exacerbations of chronic lower respiratory-tract infection in cystic fibrosis, up to 2 g every 8 hours; child 418 years 2540 mg/kg every 8 hours.
GI disturbances, allergic reactions, convulsions, disturbances in liver function tests, thrombocytopenia, neutropenia, positive Coombs test, thrombophlebitis at the site of injection among other local reactions.
Store as labelled. Keep out of reach of children.